Viewing Study NCT02583022



Ignite Creation Date: 2024-05-06 @ 7:43 AM
Last Modification Date: 2024-10-26 @ 11:51 AM
Study NCT ID: NCT02583022
Status: COMPLETED
Last Update Posted: 2015-10-21
First Post: 2015-09-30

Brief Title: A Study to Evaluate the Safety and Efficacy of PAC-14028 Cream in Atopic Dermatitis
Sponsor: Amorepacific Corporation
Organization: Amorepacific Corporation

Study Overview

Official Title: A Randomized Open-label Single Center Investigator-initiated Clinical Study to Evaluate the Safety and Efficacy of PAC-14028 Cream in Subjects With Mild to Moderate Atopic Dermatitis
Status: COMPLETED
Status Verified Date: 2015-10
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The study is a Phase II single center randomized open-label placebo-controlled study in male and female subjects aged 20 years with mild to moderate atopic dermatitis All subjects will receive BID topical applications of PAC-14028 cream or vehicle or Elidel cream for up to 4 weeks
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None